DavidPerlmutterMD · 2024-04-22 · David Perlmutter (host), Paul Fernyhough, Nigel A. Calcutt

Exciting Developments in the Treatment of Peripheral Neuropathy | Dr. Fernyhough & Dr. Calcutt

40 research-tied claims examined: 3 overstated 1 context 31 supported 5 unverified

No source found (not proven false)

0:06:16 Nigel A. Calcuttunverifiedvery low

Worldwide estimates of peripheral neuropathy prevalence range from 250 million to 500 million people.

"The worldwide incidence is difficult to estimate, but there've been estimates 250, 500 million people." (said at 0:06:16)

No published record matching the claim that worldwide estimates of peripheral neuropathy prevalence range from 250 million to 500 million people was located; this does not prove the claim false.

0:18:00 Paul Fernyhoughunverifiedvery low

Human tissue samples from patients with chemotherapy-induced neuropathy, HIV neuropathy, and diabetic neuropathy show mitochondrial abnormalities.

"And it's been shown in a number of peripheral neuropathies, certainly in chemotherapy-induced neuropathy, and I think HIV that there are in human samples mitochondrial abnormalities, and the same is true in diabetes." (said at 0:18:00)

No published record matching the claim that human tissue samples across chemotherapy-induced neuropathy, HIV neuropathy, and diabetic neuropathy show mitochondrial abnormalities was located; this does not prove the claim false.

0:29:15 David Perlmutter (host)unverifiedvery low

High salt intake raising blood sodium levels is perceived by the brain as dehydration and triggers the polyol pathway to produce endogenous fructose.

"consuming excess salt and raising your sodium level is perceived in your brain as dehydration and this activates this pathway, the polyol pathway, such that we then create fructose" (said at 0:29:15)

No published record matching the claim that excess salt consumption and elevated sodium levels trigger the polyol pathway to produce endogenous fructose as a dehydration response was located; this does not prove the claim false.

0:40:40 Nigel A. Calcuttunverifiedvery low

Pirenzepine was never approved for use in the United States by the FDA.

"It had never been used in the US. Uh it was never uh approved here." (said at 0:40:40)

No published record matching the claim that pirenzepine was never approved for use in the United States by the FDA was located; this does not prove the claim false.

0:45:40 Nigel A. Calcuttunverifiedvery low

In a clinical trial in diabetic patients with neuropathy, topical oxybutynin significantly promoted nerve regrowth in the skin compared to placebo.

"The trial was completed. And I think now that I I can say that the cuz we saw efficacy. We we saw that it helped nerves regrow in the skin of diabetic patients significantly... And it could you could measure nerve regrowth in the skin of diabetic patients that didn't happen with a placebo." (said at 0:45:40)

No published record matching a clinical trial demonstrating that topical oxybutynin significantly promoted nerve regrowth in the skin of diabetic neuropathy patients compared to placebo was located; this does not prove the claim false.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.